HighMark Wealth Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

HighMark Wealth Management’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-840	Closed	-$1.26K	–	629
2023 Q1	$1.26K	Hold	840	–	–	﹤0.01%	528
2022 Q4	$839	Hold	840	–	–	﹤0.01%	484
2022 Q3	$2K	Hold	840	–	–	﹤0.01%	453
2022 Q2	$2K	Hold	840	–	–	﹤0.01%	454
2022 Q1	$2K	Hold	840	–	–	﹤0.01%	466
2021 Q4	$4K	Sell	840 -495	-37%	-$3.1K	﹤0.01%	391
2021 Q3	$11K	Buy	1,335 +295	+28%	+$4.17K	0.01%	244
2021 Q2	$17K	Sell	1,040 -65	-6%	-$1.31K	0.01%	203
2021 Q1	$24K	Buy	+1,105	New	+$30.1K	0.02%	158

HighMark Wealth Management's TCRR Position: Q2 2023 in Review

HighMark Wealth Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 840 shares — an estimated $1.26K sold.

HighMark Wealth Management first reported a position in TCRR in Q1 2021 and held it in 9 quarters. The position peaked at $24K in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

HighMark Wealth Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
HighMark Wealth Management sold 840 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.26K.
HighMark Wealth Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 9 quarters.
HighMark Wealth Management's TCR2 Therapeutics Inc. Common Stock position peaked at $24K in Q1 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on HighMark Wealth Management's 13F filing for Q2 2023, filed 26 Jul 2023.